Population pharmacokinetics and exploratory pharmacodynamics of ifosfamide according to continuous or short infusion schedules: An n = 1 randomized study

British Journal of Clinical Pharmacology

Volumn 65, Issue 4, 2008, Pages 607-610

  Brain, Etienne G C ^a   Rezai, Kevan ^a   Lokiec, François ^a   Gutierrez, Maya ^a   Urien, Saïk ^a  

^a Rene Huguenin Centre   (France)

Author keywords

Alkylating agents; Drug metabolism; Ifosfamide; Pharmacodynamics; Pharmacokinetics; Population

Indexed keywords

IFOSFAMIDE;

ADULT; AGED; ARTICLE; BONE MARROW SUPPRESSION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOSE TIME EFFECT RELATION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG METABOLISM; DRUG SAFETY; FEMALE; HUMAN; INFUSION RATE; MALE; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NEPHROTOXICITY; NEUTROPENIA; NEUTROPHIL COUNT; OPEN STUDY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIMULATION; SOLID TUMOR;

ADULT; AGED; ANTINEOPLASTIC AGENTS, ALKYLATING; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; EPIDEMIOLOGIC METHODS; FEMALE; HUMANS; IFOSFAMIDE; LINEAR MODELS; MALE; MIDDLE AGED; NEOPLASMS, MULTIPLE PRIMARY;

EID: 40549143113     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2007.03095.x     Document Type: Article

References (6)

1. Kerbusch T, de Kraker J, Keizer HJ, van Putten JW, Groen HJ, Jansen RL, Schellens JH, Beijnen JH. Clinical pharmacokinetics and pharmacodynamics of ifosfamide and its metabolites. Clin Pharmacokinet 2001 40 : 41 62.
2. Brain EG, Rezai K, Weill S, Gauzan MF, Santoni J, Besse B, Goupil A, Turpin F, Urien S, Lokiec F. Variations in schedules of ifosfamide administration: a better understanding of its implications on pharmacokinetics through a randomized cross-over study. Cancer Chemother Pharmacol 2006 60 : 375 81.
3. Lee BS, Lee JH, Kang HG, Hahn H, Lee JH, Shin HY, Ha IS, Cheong HI, Ahn HS, Choi Y. Ifosfamide nephrotoxicity in pediatric cancer patients. Pediatr Nephrol 2001 16 : 796 9.
4. Kerbusch T, Mathot RA, Keizer HJ, Kaijser GP, Schellens JH, Beijnen JH. Influence of dose and infusion duration on pharmacokinetics of ifosfamide and metabolites. Drug Metab Dispos 2001 29 : 967 75.
5. Friberg LE, Henningsson A, Maas H, Nguyen L, Karlsson MO. Model of chemotherapy-induced myelosuppression with parameter consistency across drugs. J Clin Oncol 2002 20 : 4713 21.
6. Voelcker G, Wagner T, Wientzek C, Hohorst HJ. Pharmacokinetics of 'activated' cyclophosphamide and therapeutic efficacies. Cancer 1984 54 (6 Suppl. 1179 86.